Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market 2022-2028: Industry Analysis, Trends, Growth, Opportunities, and Forecast

The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market size is expected to grow at an annual average of 8% during 2022-2028. Alpha1-antitrypsin deficiency (AATD) is a genetic disorder characterized by low or unpredictable levels of alpha-1 protein produced by the liver. The disease most commonly affects the lungs and liver and is often undiagnosed. Augmentation therapy is the most specific therapy for the treatment of AATD and includes a variety of agents derived from human plasma.

The following segmentation are covered in this report:

By Application

• Hospitals
• Specialty Clinics
• Online Stores

By Drug Type

• Glassia
• Aralast NP
• Prolastin C
• Zemaira/Respreeza

Company Profile

• Abeona Therapeutics Inc.
• Applied Genetic Technologies Corporation
• Arrowhead Pharmaceuticals Inc.
• AstraZeneca PLC
• Baxter International, Inc.
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Chiesi Farmaceutici SpA
• CSL Behring
• Curaxys
• GlaxoSmithKline PLC

Scope of the report

The research study analyses the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent developments

• Market overview and growth analysis
• Import and export overview
• Volume analysis
• Current market trends and future outlook
• Market opportunistic and attractive investment segment

Geographic coverage

• North america market size and/or volume
• Latin america market size and/or volume
• Europe market size and/or volume
• Asia-pacific market size and/or volume
• Rest of the world market size and/or volume

Key Questions Answered by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report

• What was the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market size in 2022 and 2028; what are the estimated growth trends and market forecast (2022-2028)
• What will be the CAGR of Market during the forecast period (2022-2028)?
• Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
• Which manufacturer/vendor/players in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market was the market leader in 2022?
• Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.